Essure(R) to Be Highlighted at 18th Annual Congress of the European Society for Gynaecological Endoscopy

MOUNTAIN VIEW, Calif., Oct 29, 2009 (BUSINESS WIRE) --
CPTS | Quote | Chart | News | PowerRating -- Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure(R)
procedure, the first proven non-incisional permanent birth control
method available, today announced that the clinical success of the Essure(R)
procedure will be highlighted at the 18th Annual Congress
of the European Society for Gynaecological Endoscopy (ESGE) in Florence,
Italy from October 28-31, 2009.

The Essure(R) procedure now has 12 accepted
abstracts at ESGE from presenters across Europe recognizing the
procedure as the Gold Standard for hysteroscopic sterilization. Among
these is an oral presentation by Dr. T. Justin Clark, MRCOG, of the
Birmingham Women's Hospital. On October 30 he will be presenting his
abstract entitled, "Essure(R) Permanent Birth
Control: Worldwide Experience 2000 to 2009." The abstract will focus
on the clinical efficacy of Essure(R), zero
pregnancies in clinical studies and the 94.6% bilateral placement rate
of the device.

"I am very pleased to share my success in treating over 200 patients
with this highly effective and safe device and believe that the Essure(R)
procedure is the gold standard in treating all patients seeking
permanent sterilization," commented Dr. Clark. "The Essure(R)
device is the most effective, safe and convenient method of female
sterilization available, and should be offered to all women seeking
permanent contraception."

The Essure(R) procedure is the only procedure on
the market to have zero pregnancies in clinical trials and more than
100,000 women throughout Europe relying on the device.

About the Essure(R) Procedure

The Essure(R) procedure is a permanent birth
control method that can be done in the comfort of a physician's office
in about 13 minutes (average hysteroscopic procedure time) without
hormones, cutting, burning or the risks associated with general
anesthesia or tubal ligation. Small, flexible micro-inserts are placed
in the woman's fallopian tubes through the cervix without incisions.
Over the next three months, the body forms a natural barrier around the
micro-inserts to prevent sperm from reaching the egg. Essure is 99.8
percent effective (based on four years of follow-up) with zero
pregnancies reported in clinical trials.

Three months after the Essure procedure, a doctor performs an Essure
Confirmation Test to confirm that the fallopian tubes are fully blocked
and that the patient can rely on Essure for permanent birth
control with full confidence. Essure was FDA-approved in 2002 and
more than 340,000 women worldwide have undergone the Essure
procedure.

Essure and Conceptus(R) are registered trademarks
of Conceptus Inc.

About Conceptus, Inc.

Conceptus, Inc. (NASDAQ: CPTS), is a leader in the design, development
and marketing of innovative solutions in women's healthcare. The
Mountain View, Calif.-based company manufactures and markets Essure permanent
birth control. The Essure procedure is available in the United
States, Europe, Australia, New Zealand, Canada, Mexico, Central and
South America and the Middle East.

Please visit www.essure.com
for more information on the Essure procedure. Patients may call
the Essure Information Center at 1-877-ESSURE-1 with questions or
to find a physician in their area. Information about Conceptus is
available at www.conceptus.com.

(C)2009. All rights reserved. Conceptus and Essure are registered
trademarks and your Family is Complete your Choice is Clear is a service
mark of Conceptus Inc.

SOURCE: Conceptus, Inc.

Corporate 
Conceptus 
Gregory Lichtwardt, CFO 
650-962-4039 
glichtwardt@conceptus.com 
or 
Investor Relations 
Lippert/Heilshorn & Associates 
Kim Sutton Golodetz 
212-838-3777 
kgolodetz@lhai.com 
Bruce Voss 
310-691-7100 
bvoss@lhai.com 
or 
Media 
Conceptus 
Public Relations 
650-962-4126 
publicrelations@conceptus.com

For full details on Conceptus Inc (CPTS) CPTS. Conceptus Inc (CPTS) has Short Term PowerRatings at TradingMarkets. Details on Conceptus Inc (CPTS) Short Term PowerRatings is available at This Link.